Achieve Life Sciences (NASDAQ:ACHV) Announces Earnings Results, Beats Estimates By $0.11 EPS

Achieve Life Sciences (NASDAQ:ACHV) announced its earnings results on Tuesday. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.11, FiscalAI reports.

Here are the key takeaways from Achieve Life Sciences’ conference call:

• Achieve said its recent $180 million private placement, with up to $174 million more from milestone warrants, gives the company a strong capital base to pursue approval and launch plans.
• The company expects an FDA complete response letter tied to issues at a prior third-party manufacturer and plans to resubmit the NDA in Q4 2026 with Adare Pharma Solutions as the primary U.S. commercial supply partner.
• Management highlighted encouraging clinical and mechanistic data for cytisinicline, including selective receptor activity that may help explain its low nausea rates and strong efficacy in hard-to-treat patients who previously used varenicline or bupropion.
• Achieve is moving ahead with an independent commercial launch strategy and has added experienced leaders from Verona Pharma, including a new commercial SVP and sales leadership for the field force.
• The company reiterated plans to advance its vaping program, saying it hopes to initiate the ORCA-V2 phase III trial this year while continuing to work with FDA on timelines and trial design.

Achieve Life Sciences Price Performance

Shares of NASDAQ:ACHV traded up $0.25 on Tuesday, hitting $5.84. The stock had a trading volume of 1,885,575 shares, compared to its average volume of 968,403. Achieve Life Sciences has a twelve month low of $2.00 and a twelve month high of $6.15. The company has a debt-to-equity ratio of 0.52, a quick ratio of 4.39 and a current ratio of 4.39. The firm’s 50 day moving average price is $3.98 and its 200-day moving average price is $4.44. The company has a market capitalization of $310.86 million, a price-to-earnings ratio of -4.47 and a beta of 2.25.

Institutional Investors Weigh In On Achieve Life Sciences

Several institutional investors and hedge funds have recently made changes to their positions in ACHV. AQR Capital Management LLC bought a new position in shares of Achieve Life Sciences in the first quarter valued at about $32,000. Sender Co & Partners Inc. bought a new position in shares of Achieve Life Sciences in the second quarter valued at about $56,000. Magnolia Capital Advisors LLC bought a new position in shares of Achieve Life Sciences in the fourth quarter valued at about $64,000. Bank of America Corp DE raised its holdings in shares of Achieve Life Sciences by 39.9% in the second quarter. Bank of America Corp DE now owns 33,731 shares of the biopharmaceutical company’s stock valued at $76,000 after buying an additional 9,617 shares during the last quarter. Finally, HRT Financial LP bought a new position in shares of Achieve Life Sciences in the fourth quarter valued at about $93,000. Institutional investors and hedge funds own 33.52% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on ACHV. Canaccord Genuity Group set a $13.00 target price on shares of Achieve Life Sciences and gave the stock a “buy” rating in a research report on Monday, April 20th. Weiss Ratings lowered shares of Achieve Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday. Wall Street Zen raised shares of Achieve Life Sciences from a “strong sell” rating to a “sell” rating in a research report on Saturday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $12.00 target price on shares of Achieve Life Sciences in a research report on Thursday, April 16th. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $14.67.

About Achieve Life Sciences

Achieve Life Sciences, Inc (NASDAQ: ACHV) is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.